Special Issue "Nanobiosystems for Complex Diseases"

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: 30 September 2021.

Special Issue Editor

Dr. Lide Arana
Website1 Website2
Guest Editor
Univ Basque Country, UPV EHU, Biochem & Mol Biol Dept, Paseo de la Universidad, 7, 01006 Vitoria-Gasteiz, Spain
Interests: drug delivery systems; solid lipid nanoparticles; nanomedicine; drug targeting; sphingolipids; cell signaling; cell proliferation; cell migration

Special Issue Information

Dear colleagues,

Complex diseases are pathological processes triggered by a combination of different factors (related to environment, genetics, lifestyle, or unidentified factors) and are considered the most challenging diseases to treat. Therefore, complex diseases or pathological processes (cancer, neuropathies, multidrug resistance, or antibiotic resistance) require special efforts when it comes to developing efficient therapies. Nonetheless, recent developments in nanotechnology provide encouraging opportunities to design smart strategies for the visualization, diagnosis, or treatment of complex diseases.

This Special Issue will focus on the development of drug delivery systems designed to overcome biological barriers, increase drug efficiency, reduce side effects, improve combined therapy, or enable multitargeting strategies. Therefore, authors working on new therapeutic formulations to treat complex diseases are welcome to submit their contributions to this Special Issue entitled “Nanobiosystems for Complex Diseases”. We are especially interested in drug delivery systems that mimic structural and functional aspects of naturally occurring biological assemblies (cell membrane-based drug delivery systems, exosomes, lipid nanoparticles, liposomes, or micelles) and wish to showcase the most recent papers related to this innovative field.

Dr. Lide Arana
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • smart nanoparticles
  • nanobiosystems
  • lipid nanoparticles
  • biomimetic nanostructures
  • complex diseases
  • cancer
  • neuropathies
  • multidrug resistance
  • antibiotic resistance
  • biological barriers
  • combined therapy
  • multitarget therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Open AccessArticle
Improving Anticancer Therapy with Naringenin-Loaded Silk Fibroin Nanoparticles
Nanomaterials 2020, 10(4), 718; https://doi.org/10.3390/nano10040718 - 10 Apr 2020
Naringenin (NAR), a flavonoid present in a variety of fruits, vegetables and herbs, exhibits a wide range of pharmacological effects, including anticancer activity. Nevertheless, its application in cancer therapy is limited due to its low bioavailability at the tumour site because of its [...] Read more.
Naringenin (NAR), a flavonoid present in a variety of fruits, vegetables and herbs, exhibits a wide range of pharmacological effects, including anticancer activity. Nevertheless, its application in cancer therapy is limited due to its low bioavailability at the tumour site because of its poor solubility in water and slow dissolution rate. To improve the therapeutic efficacy of NAR, emergent research is looking into using nanocarriers. Silk fibroin (SF), from the Bombyx mori silkworm, is a biocompatible and biodegradable polymer with excellent mechanical properties and an amphiphilic chemistry that make it a promising candidate as a controlled release drug system. The aim of this work is to synthesize naringenin-loaded silk fibroin nanoparticles (NAR-SFNs) by dissolving the SF in the ionic liquid 1-ethyl-3-methylimidazolium acetate, using high-power ultrasounds and rapid desolvation in methanol followed by the adsorption of NAR. The NAR-SFNs were characterized by dynamic light scattering, Fourier transform infrared spectroscopy and thermogravimetric analysis. The drug loading content and encapsulation efficiency were calculated. The drug release profile best fitted a first order equation. The cytotoxicity effects of free NAR, bare silk fibroin nanoparticles (SFNs) and NAR-SFNs were assessed on HeLa and EA.hy926 cells via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The results demonstrated the higher in vitro anticancer potential of synthesized NAR-SFNs than that of free NAR in HeLa cancer cells. Full article
(This article belongs to the Special Issue Nanobiosystems for Complex Diseases)
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Nanobiosystems for antimicrobial drug-resistant diseases
Authors: Sophia G. Antimisiaris, I. Spiliopoulou, F. Gartziou, N. Giormezis
Affiliation: Laboratory of Pharmaceutical Technology, Department of Pharmacy, University of Patras, 26504 Rio-Patras, Greece
Abstract: Upcoming soon~

Title: Overcoming multi-resistant leishmania treatment by nanoencapsulation of potent antimicrobials
Authors: Eliana Souto
Affiliation: Universidade de Coimbra, Faculdade de Farmácia, Coimbra, Portugal
Abstract: Upcoming soon~

Title: Designing polymeric nanoparticles to cancer therapy: a positive outlook for clinical research
Authors: Enrique Niza, Iván Bravo, Carlos Alonso-Moreno
Affiliation: School of Pharmacy. University of Castilla-La Mancha, Spain
Abstract: Upcoming soon~

Back to TopTop